CTAS vs GERN · P/E 51, rev $11.26B vs rev $109.3M
Cintas Corporation (CTAS) versus Geron Corporation (GERN) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Geron Corporation (GERN) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported GERN revenue for 2026-06-30 was $109.3M. Net income was -$20.3M. GERN currently screens at market cap $878.9M.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. GERN currently screens at market cap $878.9M.
Not investment advice. Open the CTAS and GERN stock pages for the full models.
Not investment advice.